TME Pharma grants TMS exclusive negotiation rights to NOX-A12, with milestone payments up to €100M
What's the story: TME Pharma, a Berlin-based biotech developing treatments for brain cancer and eye diseases, has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotech TMS Co., Ltd. for worldwide rights to its lead cancer candidate NOX-A12. The deal was announced on 29 October 2026.
Terms: TMS pays €150,000 for six months of exclusivity to negotiate a definitive agreement. Under a non-binding term sheet, TME would receive near-term payments of approximately €10 million (cash plus an interest in a TMS subsidiary TMS is creating to finance further development of NOX-A12), up to €100 million in regulatory and commercial sales milestones, and royalties of 8–10% on sales projected to peak at around $1 billion. TME would also share any licensing fees the subsidiary receives. During the exclusivity period TME cannot negotiate with other parties.
Why it matters: NOX-A12 is TME's lead asset — an RNA-based aptamer (a short, engineered molecule that binds to a disease target, here a protein called CXCL12 that tumours use to shield themselves) in development for glioblastoma, the most aggressive form of adult brain cancer. It has US FDA Fast Track and orphan drug designations for glioblastoma, and regulators in the US and Germany have approved the design of a randomised Phase 2 trial. The agreement follows months of TME saying it was in advanced licensing talks; a definitive deal would give the cash-strapped biotech a partner to fund NOX-A12's next clinical stage while retaining royalties and milestone upside.
Read more: BioSpace, 29 October 2026